GEN reports this morning that Takeda, as previously rumored, has acquired Nycomed for $13.6 billion in cash. The deal will give Takeda a footprint in Europe and in emerging markets. Nycomed will add approximately $4 B in revenues to Takeda based on last years sales. The acquisition will effectively double Takeda's European sales.
The Nycomed product line consists of branded products in gastroenterology, respiratory and inflammatory diseases, pain, osteoporosis and tissue management. Nycomed has similar piepline products and has R&D facilities in Europe (3 sites) and in India. Manufacturing sites are in Europe (5) and in many emerging countries (10) like Brazil or Mexico. A major new plant is being built by Nycomed in Russia -- one of the four BRIC countries. Nycomed also bought a majority share early this year in a pharma company in China.
Posted by Bruce Lehr May 19th 2011.